Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.

  title={Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.},
  author={William B White and Saima Chohan and Aruna Dabholkar and Barbara Hunt and Robert Max Jackson},
  journal={American heart journal},
  volume={164 1},
Comprehensive safety evaluation of new drugs for noncardiac indications is needed in the area of cardiovascular (CV) outcomes, particularly in populations with high CV risk such as gout. Febuxostat is a potent nonpurine selective inhibitor of xanthine oxidase approved for the treatment of gout. Long-term CV safety of febuxostat is being established in a randomized, allopurinol-controlled clinical study in patients with gout who have increased CV risk using an analytical approach that provides… CONTINUE READING
Highly Cited
This paper has 46 citations. REVIEW CITATIONS
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 23 extracted citations

Management of Gout and Hyperuricemia in CKD.

American journal of kidney diseases : the official journal of the National Kidney Foundation • 2017
View 1 Excerpt


Publications referenced by this paper.
Showing 1-10 of 15 references

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, O 20 White et al American Heart

HR Schumacher, MA Becker, RL Wortmann
Journal July • 2012
View 4 Excerpts
Highly Influenced

Epidemiology of gout.

Rheumatic diseases clinics of North America • 2014
View 1 Excerpt

and Drug Administration

U. S. Foo
FDA announces new recommendations on evaluating cardiovascular risk in drugs intended to treat type 2 diabetes. Newsroom/PressAnnouncements/2008/ucm116994.htm. Last accessed May 29, • 2011
View 1 Excerpt

Febuxostat compared with allopurinol in subjects with hyperuricemia and gout

MA Becker, HR Schumacher, RL Wortmann
N Engl J Med • 2005
View 3 Excerpts